# Proactive TDM Versus Standard Use of Biologics in Psoriasis

> **NCT06398106** · PHASE4 · RECRUITING · sponsor: **University Hospital, Ghent** · enrollment: 210 (estimated)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** Proactive TDM-based dosing of secukinumab
- **DRUG:** Proactive TDM-based dosing of ixekizumab
- **DRUG:** Proactive TDM-based dosing of guselkumab

## Key facts

- **NCT ID:** NCT06398106
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-20
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398106, "Proactive TDM Versus Standard Use of Biologics in Psoriasis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06398106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*